Bronchial Responsiveness to Dry Air Hyperventilation in Smokers May Predict Decline in Airway Status Using Indirect Methods

Peter Blomstrand · Susanne Ekedahl · Birgitta Schmekel

Received: 10 August 2012 / Accepted: 24 December 2012 / Published online: 25 January 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract
Background Disabling respiratory symptoms and rapid decline of lung function may occur in susceptible tobacco smokers. Bronchial hyperresponsiveness (BHR) elicited by direct challenge methods predicts worse lung function outcomes. The aim of this study was to evaluate whether BHR to isocapnic hyperventilation of dry air (IHDA) was associated with rapid deterioration in airway status and respiratory symptoms.

Methods One hundred twenty-eight smokers and 26 age- and sex-matched healthy individuals with no history of smoking were investigated. All subjects completed a questionnaire. Spirometry and impulse oscillometry (IOS) measurements were recorded before and after 4 min of IHDA. The tests were repeated after 3 years in 102 smokers and 11 controls.

Results Eighty-five smokers (66 %) responded to the challenge with a ≥2.4-Hz increase in resonant frequency ($F_{res}$), the cutoff limit defining BHR, as recorded by IOS. They had higher $F_{res}$ at baseline compared to nonresponding smokers [12.8 ± 3.2 vs. 11.5 ± 3.4 Hz ($p < 0.05$)] and lower FEV$_1$ [83 ± 13 vs. 89 ± 13 % predicted ($p < 0.05$)]. Multivariable logistic regression analysis indicated that wheezing (odds ratio = 3.7, $p < 0.01$) and coughing (odds ratio = 8.1, $p < 0.05$) were significantly associated with hyperresponsiveness. An increase in $F_{res}$ was recorded after 3 years in responding smokers but not in nonresponders or controls. The difference remained when subjects with COPD were excluded.

Conclusions The proportion of hyperresponsive smokers was unexpectedly high and there was a close association between wheezing and coughing and BHR. Only BHR could discriminate smokers with rapid deterioration of airway status from others.

Keywords Bronchial hyperresponsiveness · Impulse oscillometry · Isocapnic hyperventilation of dry air · Resonant frequency · Tobacco smoke

Introduction
Tobacco smoking may result in significant limitation of physical performance in susceptible subjects. Hindering symptoms such as dyspnea, coughing, and attacks of wheezing and airway obstruction may occur, and some smokers may experience a faster-than-normal decline of lung function and ultimately chronic obstructive pulmonary disease (COPD), a disorder characterized by systemic and airway mucosal inflammation [1–3]. Although bronchial hyperresponsiveness (BHR) may occur in many diseases [4], it is most common in patients with inflammatory disorders of the airway mucosa. It has been reported in smokers with COPD that subjects with a faster-than-normal decline of lung function may be identified by hyperresponsiveness to methacholine or histamine [5, 6]. BHR is...
also an independent predictor of mortality in patients with COPD [7]. An extensive search for surrogate markers capable of predicting outcomes in terms of lung function in smokers has been conducted, and numerous studies on serum or sputum markers of inflammation, as well as on various tests of BHR, have been published. BHR, usually evaluated by inhalation of methacholine or histamine, has been found to occur in up to 85% of smokers with COPD [5, 8, 9]. In contrast, BHR elicited by indirect challenge methods, such as isocapnic hyperventilation of cold or dry air (IHDA), was reported to occur much less frequently; only 16% of smokers were reported to respond to IHDA with increased airway tonus [10, 11].

Responses to bronchial challenges have been measured mostly in terms of forced expiratory volume in 1 second (FEV₁), a technique that requires considerable patient cooperation. A deep inhalation preceding and/or a forced expiration during a FEV₁ maneuver may alter bronchial tone for time periods up to 6 min; this may reduce the ability of tests to correctly identify BHR [12, 13]. Impulse oscillometry (IOS) is an alternative technique to measure airway status that requires minimal patient cooperation. IOS is particularly suitable for serial measurements such as those required during a bronchial challenge [14, 15]. Airway resistance, reactance, and resonant frequency (Fres) are the outcome data; values of Fres are closely related to those of airway resistance and are defined by the frequency at which inertial forces are equal and opposite to elastic forces (i.e., reactance is zero).

The aim of this study was to evaluate whether BHR to IHDA, as measured by means of IOS, was associated with deterioration in airway status relative to baseline in a 3-year follow-up study. We also examined whether the presence of BHR was associated with subjectively perceived respiratory symptoms or reduced pulmonary function in smokers.

Materials and Methods

Subjects

One hundred ninety-eight smokers attending 11 general practitioners’ offices in Jönköping County, Sweden, were invited to participate in the study. The inclusion criterion was regular, daily tobacco smoking over at least 25 years. Subjects with severe cardiovascular, pulmonary (other than COPD), or systemic disease, those treated with corticosteroids (budesonid ≥800 µg or the equivalent), and those with physician-diagnosed asthma were not included. Forty-four subjects (30 women and 14 men) refrained from participation due to personal reasons. Data from a further 26 smokers (23 women and 3 men) were excluded because it was missing or the pulmonary function recordings were nonreproducible. A complete dataset was recorded for 76 women and 52 men (Table 1). Thirty-five age- and sex-matched subjectively healthy individuals with no history of smoking were enrolled as controls, nine of whom were excluded due to nonreproducible pulmonary function recordings. A complete dataset was recorded in 17 female and 9 male healthy controls. Baseline pulmonary function tests were repeated after approximately 3 years in 102 smokers and 11 healthy nonsmokers. Fifteen smokers had stopped smoking between 1 and 26 weeks prior to the first visit and 12 had ceased smoking >12 months prior to the second visit. Only four smokers refrained completely from smoking during the 3-year observation period. Body mass index (BMI) was defined as the subject’s body mass (kg) divided by the square of his or her height (m).

All subjects completed a questionnaire regarding their medical history, including drug therapy, smoking habits, and respiratory symptoms. Three standardized questions concerning symptoms associated with COPD were selected from the International Primary Care Airways Group Handbook [16]: (1) Does the weather affect your cough? (2) Do you ever cough up phlegm from your chest when you do not have a cold? (3) Do you usually cough up phlegm from your chest in the morning? Three additional questions were asked: Do you usually experience wheezing? Do you usually have breathing problems? Do you usually experience shortness of breath when you have a cold?

A 3-week period free from the common cold was required to precede the tests. Patients were asked not to use β₂-agonists, drink xanthine-containing beverages, or smoke during the 12 hours prior to the tests. All measurements were carried out during a single day at the Department of Clinical Physiology, County Hospital Ryhov, Jönköping, Sweden. The study complied with the Declaration of Helsinki and was approved by the Regional Ethics Research Committee at Linköping. All subjects gave written informed consent before inclusion in the study.

Pulmonary Function Tests

Spirometry and IOS measurements were performed using a Masterscreen-IOS device (E. Jaeger GmbH, Wurzburg, Germany). FEV₁ and vital capacity measurements were performed according to clinical routine and guidelines of the American Thoracic Society and European Respiratory Society [17, 18]. Spirometry data are given as a percentage of reference values as documented in a national nonsmoking reference population [19, 20]. The Fres was determined by means of IOS [14, 15, 21]. The subjects wore a nose clip and supported their cheeks with their hands. Pressure impulses were then applied to the respiratory system via a mouthpiece during tidal breathing. The responding signal
was measured with a pneumotachograph and pressure transducer. $F_{\text{res}}$ was calculated from the pressure-flow relationship by using a fast Fourier transformation. Measurements were repeated at least three times at baseline and a representative $F_{\text{res}}$ value was selected. Measurements were also repeated 2, 4, and 6 min after IHDA, and the highest, most appropriate values were selected. Based on duplicate measurements of responses to challenge in healthy nonsmoking controls, a significant change in $F_{\text{res}}$ and a cutoff limit for BHR were defined by an increase in $F_{\text{res}}$ of $\pm 2.4$ Hz (i.e., $3 \times$ standard deviation [SD] diff), which corresponds to an increase of approximately 20 %.

Hyperventilation Challenge

All subjects were encouraged to breath through a mouthpiece at a rate of $\sim 28$ breaths/min for 4 min. A gas mixture containing 21 % $O_2$, 5 % $CO_2$, and 74 % $N_2$ was delivered through a calibrated rotameter to a meteorological reservoir balloon (Ailos Asthma Test 22 000; Karlstad, Sweden) and directed to the subject. The target ventilation was set to $24 \times FEV_1$ (i.e., 70 % of maximal voluntary ventilation) and subjects were encouraged to deflate the balloon.

Statistical Analysis

Data are presented as mean and standard deviation, 95 % confidence interval, or median [lower—upper quartile]. The Mann–Whitney $U$ test was used to test differences among numerical variables, and Fisher’s exact test was used for binary variables. Univariable and multivariable logistic regression analyses were used to determine whether any variable was associated with BHR, and the results were expressed as odds ratios. Pearson’s correlation coefficient was calculated to study the association between responses to challenge and pulmonary function. Receiver-operated curve (ROC) analyses were performed to identify smokers with rapid deterioration in airway status. A $p$-value of $\leq 0.05$ was considered to be statistically significant. Two-sided tests were used throughout. Statistical analyses were performed using the commercially available statistical programs STATISTICA version 9 (StatSoft Inc., Tulsa, OK, USA, www.statsoft.com) and SAS/Stat software version 9.2 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA). ROC analyses were performed using MedCalc Statistical Software (Mariakerke, Belgium).

Results

Demographic characteristics, respiratory symptoms, and the results of pulmonary function tests in 128 smokers and 26 healthy nonsmoking volunteers are given in Table 1. All subjects were Caucasians. The smokers smoked $14 \pm 8$ cigarettes per day and had been smoking for $41 \pm 7$ years. Thirty-eight smokers smoked less than 10 cigarettes per day.

Eighty-five smokers showed significant increases in $F_{\text{res}}$ (i.e., $\geq 2.4$ Hz) after IHDA and were classified as “responders” (BHR+). The remaining 43 smokers constituted a group of “nonresponders” (BHR−; Fig. 1). Respiratory symptoms were more common in responders than in nonresponders, and responders also had worse pulmonary function at baseline than did nonresponders ($p < 0.05$; Table 2). Responses to challenge were not associated with
baseline values of either $F_{\text{res}}$ or FEV$_1$ ($r = 0.07, p > 0.05$ or $r = -0.13, p > 0.05$). Female smokers outnumbered male smokers, and they had been regular smokers for a shorter period of time than male smokers ($40 \pm 7$ vs. $43 \pm 6$ years, $p < 0.05$); however, there were no gender-related differences in pulmonary function or IHDA response. Twenty-nine smokers fulfilled the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for COPD, 24 of whom were responders [22].

Wheezeing was the most commonly perceived symptom (Table 3), and wheezers had a higher body mass index (BMI), worse pulmonary function, and more pronounced responses to challenge than nonwheezers. Furthermore, coughing was associated with worse hyperresponsiveness ($p < 0.001$). In contrast, there was no association between coughing and BMI, longer tobacco smoke exposure, or current smoking habits.

A univariable logistic regression analysis was performed to analyze the association between BHR and respiratory symptoms, pulmonary function, and gender in smokers (Table 4). These variables were also used in a multivariable logistic regression analysis, the results of which indicated that wheezing (odds ratio $= 3.7, p < 0.01$) and coughing affected by weather (odds ratio $= 8.1, p < 0.05$) should remain in the logistic regression model; these factors were significantly associated with hyperresponsiveness. The odds ratio of BHR in smokers with a combination of symptoms of wheezing and weather-induced cough was 21.2 times that calculated in smokers not experiencing these symptoms.

One hundred two of the 128 smokers and 11 of the 26 healthy volunteers repeated the tests approximately 3 years after the first visit. Baseline pulmonary function, as determined by the pretest $F_{\text{res}}$ value, deteriorated significantly more in responders [median (lower to upper quartile, $p = 0.03$) $= 1.1 (-0.6$ to $+4.0$ Hz)] than in nonresponders [0.2 $(-1.0$ to $+1.5$ Hz) during this time period. The corresponding change in healthy volunteers was $[-0.1 (0.07$ to $+0.6$ Hz)]. There was no significant decline in FEV$_1$ (% predicted) after 3 years in responding smokers, nonresponding smokers, or healthy volunteers $[-1.1 (-6.0$ to $+4.0$) % and $-1.0 (-6.4$ to $+3.0$) % vs. 1.5 $(-7.6$ to $+5.2$) %]. Responsiveness to IHDA, but none of the other tests or demographic data recorded at baseline during the first visit, was capable of discriminating between those who experienced worsening airway status and those who did not, as defined by $F_{\text{res}}$ at baseline, after the 3-year observation period. There was a small but not statistically significant difference in deterioration of pulmonary function after 3 years between responding and nonresponding smokers when subjects with COPD were excluded from evaluation $[0.7 (-0.6$ to $+3.9$) vs. $-0.1 (-0.9$ to $+1.6$ Hz) ($p = 0.1$)].

Based on the assumption that pulmonary function may deteriorate in some of the smokers, even during such a short period of time as 3 years, a ROC analysis was performed using significant worsening of the pretest value of $F_{\text{res}}$ (i.e., increases in baseline $F_{\text{res}} \geq 2.4$ Hz) over time as the classification variable. ROC analyses revealed an alternative cutoff level of $\geq 3.8$ Hz for the $F_{\text{res}}$ increase. Using the alternative cutoff level, 65 smokers instead of 85 would be defined as hyperresponsive to IHDA at the first visit. The majority (51 %) of all responding smokers had an $F_{\text{res}}$ increase after challenge exceeding 3.8 Hz. This higher threshold level yielded an area under the ROC curve (AUC) of 0.66 (standard error [SE] = 0.05), sensitivity of 53 %, and specificity of 85 %. As a comparison, the corresponding AUC calculated using the main criterion (i.e., response to IHDA in individuals with $F_{\text{res}} \geq 2.4$ Hz) was 0.63 (SE = 0.06), and the sensitivity and specificity were 47 and 92 %, respectively. Hyperresponsive smokers, as defined by the higher threshold level, experienced significantly greater worsening of the baseline airway status than those with $F_{\text{res}}$ increases below this threshold (baseline $F_{\text{res}}$ changes between the two study days $[2.5 (-0.3$ to $+4.5)$ vs. $0.1 (-1.1$ to $+1.6$ Hz $p = 0.005]$). The difference between the groups remained when smokers with COPD were excluded from evaluation $[1.0 (-0.4$ to $+4.1)$ vs. $0.1 (-1.0$ to $+1.6$ Hz $p = 0.05]$]. There were no differences in the baseline FEV$_1$ values recorded during the second visit between these two subgroups of smokers ($p > 0.05$).
Table 2 Characteristics, respiratory symptoms, and pulmonary function in smokers with (BHR+) and without (BHR−) bronchial hyperresponsiveness

| Characteristics             | Smokers BHR+ (n = 85) | Smokers BHR− (n = 43) | p     |
|-----------------------------|-----------------------|-----------------------|-------|
| **Age (years)**             | 57 ± 7 ns             | 58 ± 8                |       |
| **Sex (female/male)**       | 50/35 ns              | 26/17                 |       |
| **BMI**                     | 26 ± 4 ns             | 25 ± 3                |       |
| **Smoke years**             | 41 ± 7 ns             | 41 ± 7                |       |
| **Cigarettes/day**          | 14 ± 9 ns             | 13 ± 8                |       |
| **β2-agonists**             | 15 ** 0              |                       |       |
| Cough affected by weather   | 19 ** 1              |                       |       |
| Phlegm cough without cold   | 54 ** 17             |                       |       |
| Phlegm cough in the morning | 40 ns 16             |                       |       |
| Wheeze                      | 67 *** 19             |                       |       |
| Breathing problems          | 26 * 6               |                       |       |
| Shortness of breath on cold | 41 ns 13             |                       |       |
| **FEV1 (% predicted)**      | 83 ± 13 * 89 ± 13     |                       |       |
| **FEV1/VC (% predicted)**   | 92 ± 11 * 98 ± 8      |                       |       |
| **Fres baseline (Hz)**      | 12.8 ± 3.2 * 11.5 ± 3.4|                      |       |

Values are mean ± standard deviation or number of subjects, unless otherwise stated

BMI body mass index β2-agonists subjects undergoing β2-agonist treatment, FEV1 forced expiratory volume during 1 second, VC vital capacity, Fres resonant frequency, ΔFres change in Fres after bronchial challenge

Table 3 Characteristics and pulmonary function in smokers with and without subjectively perceived wheezing

| Characteristics         | Wheezers (n = 86) | p | Nonwheezers (n = 42) |
|-------------------------|------------------|---|----------------------|
| **Age (years)**         | 57 ± 8           | ns         | 58 ± 7               |
| **BMI**                 | 26 ± 4 **        | 24 ± 4     |
| **Smoke years**         | 41 ± 7           | 41 ± 7     |
| **Cigarettes/day**      | 16 ± 8 **        | 10 ± 8     |
| **β2-agonists**         | 15 ** 0         | 0         |
| **FEV1 (% predicted)**  | 83 ± 14 **      | 90 ± 11    |
| **FEV1/VC (% predicted)**| 93 ± 11         | 96 ± 8     |
| **Fres baseline (Hz)**  | 12.9 ± 3.3 **    | 11.2 ± 3.0 |
| **ΔFres (Hz)**          | 4.9 ± 3.5 ***    | 2.5 ± 2.6  |

Values are mean ± standard deviation or number of subjects, unless otherwise stated

BMI body mass index β2-agonists subjects undergoing β2-agonist treatment, FEV1 forced expiratory volume during 1 second, VC vital capacity, Fres resonant frequency, ΔFres change in Fres after bronchial challenge

*p < 0.05, **p < 0.01, ***p < 0.001, ns not statistically significant

Discussion

Thresholds for classification of results from bronchial challenge are arbitrary, and optimum cutoff levels must be chosen depending on the challenge method used [23]. Measurements of IHDA responses most often have been achieved by means of forced expirations, and a 12 % decrease in FEV1 has been reported to be an optimal cutoff level [23]. We used IOS for the detection of responses and defined a positive response as an increase in Fres of at least 2.4 Hz, corresponding to a 20 % increase. Eighty-five of 128 (66 %) smokers were then recognized as responders, and this threshold distinctly discriminated healthy individuals with no smoking history from responding smokers. Pulmonary function at baseline, as determined by Fres, deteriorated significantly during a 3-year observation period in BHR+ smokers but not in BHR− smokers or healthy volunteers. Although increases in baseline Fres were modest, this still suggests that the cutoff limit of 2.4 Hz is clinically relevant, provided that a true deterioration of pulmonary function occurred during this relatively short period of time in BHR+ smokers, despite that FEV1 recordings were not significantly decreased in the follow-up visit. The fact that Fres increased significantly in BHR+ smokers during the observation period but FEV1 remained unchanged tends to confirm that the IOS technique is more sensitive than forced expirations in measuring changes in airway function [14, 21, 24]. Furthermore, as an additional sign of the higher sensitivity of the IOS method compared to FEV1, we found only a weak association between the levels of BHR and impaired pulmonary function at baseline, confirming the view that IOS recordings are independent of airflow and/or the pre-challenge caliber of airways. A supplementary ROC analysis revealed that a Fres cutoff value of 3.8 Hz identified 65 of 128 smokers (51 %) as responders. The requirement of a smaller decrease in Fres to define BHR+ would capture more cases of reactive airways (increased sensitivity) but would also include some “normal” responses (decreased specificity). We found no major differences in accuracy calculated with these two different threshold levels, and therefore the final choice of cutoff level may remain unclear until a longer observation period has passed to enable confirmation of the clinical significance of the decline in airway status. Pulmonary function deteriorated in hyperresponsive smokers, even when subjects with COPD were excluded. Hyperresponsiveness to IHDA
determined by IOS therefore appears to be a risk factor for deterioration of pulmonary function in smokers independent of baseline airway status or COPD. The proportion of responders was unexpectedly high considering that most of our smokers had only mild signs of smoke-elicited injuries. The prevalence of BHR after hyperventilation of cold air was previously reported to be approximately 15% of smokers with chronic bronchitis or COPD. However, responses to challenge were measured by means of FEV\textsubscript{1}, which may underestimate the true response [25]; this could explain the low proportion of responders among smokers upon indirect challenge in previous studies [10, 26, 27]. Therefore, the large variability in BHR prevalence might depend at least partly on the methodological limitations of the forced expiration technique, since airway tonus may change after a deep inspiration that precedes the FEV\textsubscript{1} maneuver [28, 29]. Furthermore, responses to deep inspirations have been reported to decrease with COPD severity [30], and this may result in a larger variability in BHR prevalence depending on differences in age distribution among the various study populations. Therefore, it is concluded that variability in BHR prevalence among smokers may originate from differences in challenge methods, choice of threshold levels, and/or measurement techniques, apart from the phenotypical differences in populations of smokers.

There are methodological shortcomings of the IHDA technique per se that result from technical difficulties in measuring and controlling airflow or alternating volumes of exhaled warm humid air and inhaled dry cold air; this makes the determination of “challenge doses” complex. Although subjects were encouraged to reach the target level of ventilation, some of them failed and inhaled less than intended; this may have introduced a type II error leading to underestimation of the number of hyperresponsive subjects. Furthermore, the selection of subjects in our study was not population-based. We recruited smokers seeking primary health care, and selection bias theoretically might have occurred because patients with asthma or other diseases were excluded based mainly on clinical grounds. All our subjects were Caucasians and there might be racial differences in vulnerability to tobacco smoke [31]. We did not assess diet or passive tobacco smoke exposure during childhood, factors that may influence susceptibility. Twenty-three smokers tried to quit smoking but only four succeeded to refrain completely from smoking during the 3-year observation period. We could not show that temporary or permanent cessation of smoking changed the pulmonary function results between the two study days, probably because there were too few who refrained completely from smoking. Smoking cessation prevents accelerated decline in lung function in all smokers [32]. We did not exclude smokers who refrained from smoking. We also judged that the dropout rate of 20% among our smokers in the 3-year observation period was fairly large (though acceptable). Despite the fairly large dropout rate, the number of remaining subjects allowed us to also use data recorded during the second visit to the laboratory.

Intermittent wheezing was the most common symptom reported by the smokers, and there was a close association between respiratory symptoms and BHR. Odds ratios for the presence of BHR ranged from 3 to 20 if there was a simultaneous history of either wheezing and/or coughing. This may suggest parallel events and/or common underlying mechanisms of these particular symptoms and bronchial contractions elicited by IHDA. Generally, wheezers had a worse airway status, consistent with the view that wheezing may be a sign of airway obstruction [6]. Wheezers also had a higher BMI than nonwheezers, but there was no difference in BMI between responders and nonresponders. Obesity per se may be a risk factor for airways obstruction and wheezing but not for hyperresponsiveness [33, 34]. Our results are comparable to previously published data in a population-based longitudinal study using histamine challenge in the sense that hyperresponsive subjects tended to develop respiratory symptoms more often than those with no proven BHR [6].

We observed significant deteriorations in baseline pulmonary function as assessed by IOS in responders, but not in nonresponders or healthy volunteers, and this divergence occurred after just a 3-year observation period. It is therefore concluded that responsiveness to IHDA in smokers may predict a decline in airway status over such a short period of time. It is not known if BHR to IHDA is associated with a worse prognosis in the long run, corresponding to previous findings in studies on BHR to

---

**Table 4** Odds ratios (OR) of bronchial hyperresponsiveness to hyperventilation of dry air associated with respiratory symptoms, pulmonary function, or gender presented with 95% confidence intervals (95% CI), based on univariable logistic regression in smokers.

| Symptom                               | OR     | 95% CI          | p     |
|---------------------------------------|--------|-----------------|-------|
| Cough affected by weather             | 12.3   | [1.6–95.0]      | 0.01  |
| Phlegm cough without cold             | 2.8    | [1.3–5.9]       | 0.01  |
| Phlegm cough in the morning           | 1.5    | [0.7–3.2]       | ns    |
| Wheeze                                | 4.7    | [2.1–10.4]      | 0.0001|
| Breathing problems                    | 2.7    | [1.0–7.2]       | 0.05  |
| Shortness of breath on cold           | 2.1    | [1.0–4.7]       | 0.06  |
| FEV\textsubscript{1} < 80% predicted  | 2.0    | [0.9–4.6]       | 0.09  |
| FEV\textsubscript{1}/VC < 70%         | 1.9    | [0.9–4.4]       | 0.09  |
| Sex, female gender                    | 0.9    | [0.4–2.0]       | ns    |

FEV\textsubscript{1} forced expiratory volume during 1 second, VC vital capacity ns not statistically significant.
methacholine challenge [5]. The IOS technique requires minimal patient cooperation, is particularly suitable for serial measurements such as those required during a bronchial challenge, and tends to be more sensitive than forced expirations in measuring discrete changes in airway function. Although such changes may be detected by IOS, the final long-term clinical relevance of the presence of BHR detected by IHDA is not known. Future studies on the long-term effect of smoking on BHR to IHDA and airway status may determine whether the choice of the cutoff limit of \( F_{\text{res}} \) after challenge indicates a true increased risk for the subject.

**Acknowledgments** Mrs Rebecca Lewis is acknowledged for technical assistance and Mr. Mats Nilsson for statistical support. Financial support was provided by Futurum, the Academy of Healthcare, Jönköping County Council, and FORSS, the Medical Research Council of Southeast Sweden.

**Conflict of interest** The authors have no conflicts of interest or financial ties to disclose.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. van Schayck CP, Halbert RJ, Nordyke RJ, Isonaka S, Maroni J, Nonikov D (2005) Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting. Respir Care 10(3):323–333. doi:10.1111/j.1440-1843.2005.00720.x

2. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. Chest 131(5):1557–1566. doi:10.1378/chest.06-2179

3. Walter RE, Wilk JB, Larson MG, Vasan RS, Keanney JF Jr, Lipinska I, O’Connor GT, Benjamin EJ (2008) Systemic inflammation and COPD: the Framingham Heart Study. Chest 133(1):19–25. doi:10.1378/chest.07-0058

4. Ludviksdottir D, Janson C, Bjorntsson E, Stalenheim G, Boman G, Hedenstrom H, Venge P, Gudbjornsson B, Vallysodottir S (2000) Different airway responsiveness profiles in atopic asthma, nonatopic asthma, and Sjogren’s syndrome. BHR Study Group. Bronchial hyperresponsiveness. Allergy 55(3):259–265

5. Tashkin DP, Altose MD, Connert JE, Kanner RE, Lee WW, Wise RA (1996) Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 153(6 Pt 1):1802–1811

6. Xu X, Rijcken B, Schouten JP, Weiss ST (1997) Airways responsiveness and development and remission of chronic respiratory symptoms in adults. Lancet 350(9089):1431–1434

7. Hopsers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP (2000) Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 356(9238):1313–1317

8. Tashkin DP, Altose MD, Bleecker ER, Connct JE, Kanner RE, Lee WW, Wise R (1992) The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 145(2 Pt 1):301–310

9. Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP, Wise RA (1994) Gender difference in airflow hyperresponsiveness in smokers with mild COPD. The lung health study. Am J Respir Crit Care Med 150(4):956–961

10. Ramsdale EH, Morris MM, Roberts RS, Hargreave FE (1984) Bronchial responsiveness to methacholine in chronic bronchitis: relationship to airflow obstruction and cold air responsiveness. Thorax 39(12):912–918

11. Kostikas K, Koutsounoubou S, Karamanis T, Papatheodorou G, Loukides S (2008) Isocapnic cold air challenge in patients with COPD: are there any predisposing factors? COPD 5(3):171–176. doi:10.1080/15412550802093009

12. Orehek J, Nicoli MM, Delpierre S, Beaupre A (1981) Influence of the previous deep inspiration on the spirometric measurement of provoked bronchoconstriction in asthma. Am Rev Respir Dis 123(3):269–272

13. Malmberg P, Larsson K, Sundblad BM, Zhiping W (1993) Importance of the interval time between FEV1 measurements in a methacholine provocation test. Eur Respir J 6(5):680–686

14. Kohlihäufl M, Brand P, Scheuch G, Schulz H, Haussinger K, Heyder J (2001) Impulse oscillometry in healthy nonsmokers and asymptomatic smokers: effects of bronchial challenge with methacholine. J Aerosol Med 14(1):1–12

15. Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, Marchal F, Measurements ERSTFrO (2003) The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 22(6):1026–1041

16. International Primary Care Airways Group. The IPAG Handbook. Available at http://www.ipagguide.org/. Accessed September 2, 2012

17. Quanjer P (1983) Standardized lung function testing. Report working party. Bull Eur Physiopathol Respir 19(Suppl 5):1–95

18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J (2005) Standardisation of spirometry, Eur Respir J 26(2):319–338. doi:10.1183/09031936.05.00034805

19. Hedenstrom H, Malmberg P, Agarwal K (1985) Reference values for lung function tests in males. Regression equations with smoking variables. Bull Eur Physiopathol Respir 21(6):551–557

20. Hedenstrom H, Malmberg P, Fridriksson HV (1986) Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci 91(3):299–310

21. Schmeka B, Smith HJ (1997) The diagnostic capacity of forced oscillation and forced expiration techniques in identifying asthma by isocapnic hyperpnoea of cold air. Eur Respir J 10(10):2243–2249

22. Global Initiative for Chronic Obstructive Lung Disease. (2011) Available at http://www.goldcopd.org/Guidelines/guidelines-resources.html. Accessed December 2011

23. Eliaosso AH, Phillips YY, Rajagopal KR, Howard RS (1992) Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm. Chest 102(2):347–355

24. Pennings HJ, Wouters EF (1997) Effect of inhaled beclomethasone dipropionate on isocapnic hyperventilation with cold air in asthmatics, measured with forced oscillation technique. Eur Respir J 10(3):665–671

25. Evans TM, Rundell KW, Beck KC, Levine AM, Baumann JM (2005) Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. Chest 128(4):2412–2419. doi:10.1378/chest.128.4.2412
26. Hassan NM, Hargreave FE, Nair P (2010) Airway responsiveness to indirect challenges in COPD. COPD 7(2):133–140. doi: 10.3109/15412551003631741

27. Scichilone N, Battaglia S, La Sala A, Bellia V (2006) Clinical implications of airway hyperresponsiveness in COPD. Int J Chron Obstruct Pulmon Dis 1(1):49–60

28. Crimi E, Pellegrino R, Milanese M, Brusasco V (2002) Deep breaths, methacholine, and airway narrowing in healthy and mild asthmatic subjects. J Appl Physiol 93(4):1384–1390. doi: 10.1152/japplphysiol.00209.2002

29. Scichilone N, Marchese R, Catalano F, Vignola AM, Togias A, Bellia V (2004) Bronchodilatory effect of deep inspiration is absent in subjects with mild COPD. Chest 125(6):2029–2035

30. Scichilone N, La Sala A, Bellia M, Fallano K, Togias A, Brown RH, Midiri M, Bellia V (2008) The airway response to deep inspirations decreases with COPD severity and is associated with airway distensibility assessed by computed tomography. J Appl Physiol 105(3):832–838. doi:10.1152/japplphysiol.01307.2007

31. Dransfield MT, Davis JJ, Gerald LB, Bailey WC (2006) Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir Med 100(6):1110–1116. doi:10.1016/j.rmed.2005.09.019

32. Willemse BW, Postma DS, Timens W, ten Hacken NH (2004) The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 23(3):464–476

33. Schachter LM, Salome CM, Peat JK, Woolcock AJ (2001) Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax 56(1):4–8

34. Thyagarajan B, Jacobs DR Jr, Apostol GG, Smith LJ, Jensen RL, Crapo RO, Barr RG, Lewis CE, Williams OD (2008) Longitudinal association of body mass index with lung function: the CARDIA study. Respir Res 9:31. doi:10.1186/1465-9921-9-31